Sexual function — peptide, drug, hormonal, and lifestyle options compared

Sexual function complaints — desire, arousal, erection quality, anorgasmia — span four distinct domains, and almost every adopter conflates them. Desire is a brain question (dopaminergic, hormonal, contextual). Arousal is partly central and partly autonomic. Erection / lubrication is mostly vascular. Orgasm is partly autonomic and partly central. Asking "what's the best compound for sex" without specifying which of these is the actual complaint is the most common framing error in this category, and it leads people to the wrong tool.

The peptides in this category target two of the four domains: PT-141 (bremelanotide) acts centrally on melanocortin receptors and primarily affects desire and arousal. The PDE5 inhibitor class (sildenafil, tadalafil, vardenafil) acts peripherally on vascular smooth muscle and affects erection quality only. These tools are complementary, not interchangeable, and the right choice depends on which sub-complaint dominates.

This guide compares the realistic options. It is structured around a load-bearing observation: the most common cause of sexual function complaints in adults is not a sex-specific problem. It is one or more of the following: sleep deprivation, alcohol use, chronic stress, untreated depression, certain medications (SSRIs, opioids, beta-blockers, antihistamines), undiagnosed hormonal issues (hypogonadism, thyroid dysfunction), cardiovascular disease (erection issues precede measured cardiovascular events by ~3 years on average), or relationship context. Pharmacological intervention without addressing the upstream cause produces a partial result that decays.

The comparison

Option	Evidence tier	Acts on which domain	Onset / duration	Cost / month (US, 2026 est.)	Side effects	Dependence / rebound	Who should consider	Who should skip
Lifestyle audit (sleep, alcohol, cardio, stress)	Tier 1	All four; addresses root cause	4–12 weeks	$0	None	None	Everyone	No one
Medication review (SSRI, opioids, beta-blockers, antihistamines, finasteride)	Tier 1 for each as a sexual-side-effect driver	All four; addresses cause	Variable	Often free (switch or dose adjustment)	Switching SSRIs has its own discontinuation considerations	None directly	Anyone on a medication with known sexual side effects, with sexual complaint	Anyone whose medication is medically necessary without alternatives
Cardiovascular workup (lipids, hypertension, glucose, smoking)	Tier 1	Erection (vascular)	12–26 weeks of treatment	$50–300	Per-medication	None	Men 40+ with erection-quality decline, men with cardiovascular risk factors	No one with new-onset ED — workup is non-optional
Hormonal workup (testosterone, prolactin, thyroid, estradiol)	Tier 1	Desire (primarily); some erection effects	12–26 weeks of treatment	$50–500 with insurance	Per-intervention	Variable	Anyone with sexual complaint + fatigue / mood / cognitive symptoms; presumed hypogonadism	Self-treatment without lab workup
PDE5 inhibitors — sildenafil (Viagra)	Tier 1 (one of the most-studied drugs in human history)	Erection only	Onset 30–60 min; lasts 4–6 hr	$10–80 (generic)	Headache (~16%), flushing, dyspepsia, vision changes (rare); contraindicated with nitrates	Low	Erection-quality complaint specifically; cardiovascular-disease comorbidity check first	Active nitrate use; severe cardiovascular instability; severe hepatic impairment
PDE5 — tadalafil (Cialis), daily 5 mg	Tier 1	Erection only	36 hr active; daily dose builds steady state	$20–100 (generic); $200+ branded	Same as sildenafil; lower-grade because lower peak dose	Low	Frequent activity; spontaneity preferred; can also improve LUTS (BPH) symptoms	Same as sildenafil
PDE5 — vardenafil (Levitra)	Tier 1	Erection only	Similar to sildenafil; 4–5 hr	$20–80	Same class profile	Low	Sildenafil non-responders; some prefer the side-effect profile	Same as sildenafil
PT-141 / bremelanotide (FDA-approved as Vyleesi for HSDD in women; off-label use across both sexes)	Tier 1 for HSDD on-label (Kingsberg 2019 RECONNECT phase-3); Tier 3 off-label for men's sexual function	Desire and arousal (central; melanocortin pathway)	Onset 30–60 min; effect lasts 2–6 hr; peak ~2 hr	$300–600 branded; $30–60/cycle research suppliers	Nausea (~40%, worst first dose), headache, flushing, transient BP rise (2–6 mmHg systolic), pigmentation changes (chronic use), hyperpigmentation of nipples / mole darkening	Tachyphylaxis with frequent use; community caps at 4–8 doses/month	Desire / arousal complaint where erection is not the issue; PDE5 non-responders for the central component; HSDD in premenopausal women (on-label)	Uncontrolled hypertension; cardiovascular instability; pregnancy; women postmenopausal (efficacy unclear); anyone seeking erection-only effect (wrong tool)
Testosterone replacement (medical)	Tier 1 for lab-confirmed hypogonadism	Desire (primarily); some erection	12–26 weeks	$30–200 with insurance; $150–400 cash	Hematocrit elevation, lipid shifts, fertility suppression, cardiac and prostate monitoring	Reversible on stop; HPGA recovery variable	Lab-documented hypogonadism + clinical symptoms (desire, fatigue, mood); managed by a physician	"Normal-low" testosterone without symptoms; self-treatment without workup; women without hormone-specialist guidance
Bupropion (Wellbutrin, sometimes co-prescribed)	Tier 2 (small RCTs in SSRI-induced sexual dysfunction)	Desire; mitigation of SSRI sexual side effects	4–8 weeks for full effect	$20–50 (generic)	Insomnia, anxiety, dry mouth, very rare seizure	Modest discontinuation effects	SSRI-induced sexual dysfunction; add-on or switch	Seizure history; active eating disorder; bipolar without mood stabilizer
Psychological support (sex therapy, CBT, couples therapy)	Tier 1 for relationship-context complaints; Tier 2 for performance anxiety	All four; addresses cognitive component	8–24 weeks	$1500–4000 over a course	None	None	Anyone with relationship context driving the complaint; performance anxiety; trauma-related issues	No one for whom the cognitive / relational layer is part of the picture
Choosing acceptance / context check	Tier 1 in honesty	All four	Immediate	$0	None	None	People whose libido / function has shifted in a way that maps to age, life stage, or relationship — and whose health metrics are normal	Anyone with sudden onset or progressive decline (workup non-optional)

The top four rows handle ~70% of sexual function complaints when they are the actual problem and have been ignored. The pharmacological rows are most defensible after the top four have been worked through.

This guide carries the public comparison. The member continuation walks the PT-141 case in depth, the PDE5 vs PT-141 mechanism split, the women's sexual function conversation (separately, because the literature and the regulatory pathway differ), and the founder's view.